Lipid-complexed camptothecin: formulation and initial biodistribution and antitumor activity studies

Area of Science:

• Oncology
• Drug Delivery
• Pharmacology

Background:

• Camptothecin (CPT) derivatives are potent topoisomerase I inhibitors with broad anticancer activity.
• Early CPT formulations faced challenges including severe toxicity (cystitis, gastroenteritis, leukopenia) and reduced efficacy.
• The water-insoluble lactone form of CPT exhibits greater activity than its water-soluble sodium salt.

Purpose of the Study:

• To develop and characterize a novel lipid-complexed camptothecin (LC-CPT) formulation.
• To evaluate the in vitro and in vivo antitumor efficacy and biodistribution of LC-CPT.
• To compare the activity and toxicity profile of LC-CPT with free CPT.

Main Methods:

• Preparation of lipid-complexed CPT (LC-CPT) with a particle size range of 20.8-208.1 nm.
• Assessment of in vitro antitumor activity and cytotoxicity against MDR-1-negative and -positive tumor cells.
• Evaluation of CPT biodistribution following intravenous administration of free CPT and LC-CPT.
• Testing of in vivo antitumor activity of LC-CPT against intraperitoneal L1210 and P338 leukemia models.

Main Results:

• LC-CPT demonstrated in vitro antitumor activity comparable to non-lipid-formulated CPT.
• Lipid complexation significantly altered CPT biodistribution, with LC-CPT accumulating in the gastrointestinal tract.
• LC-CPT exhibited significant in vivo antitumor activity against L1210 and P338 leukemia.
• LC-CPT appeared more potent than free CPT in vivo.

Conclusions:

• Lipid complexation offers a promising approach for formulating camptothecin derivatives.
• LC-CPT is easily prepared, suitable for intravenous administration, and shows enhanced antitumor potency.
• This formulation may overcome limitations of earlier CPT delivery systems, potentially improving therapeutic outcomes.